FIELD: immunotherapy.
SUBSTANCE: use of NOX inhibitor selected from NOX4 inhibitor, NOX4/1 inhibitor, and NOX1 inhibitor is disclosed for the treatment of cancer forms, such as solid tumor or hematological malignant neoplasms showing or inclined to show the resistance to immunotherapy or to an antiangiogenic agent, where the specified NOX4, NOX4/1, or NOX1 inhibitor is to be administered in a combination with an anticancer immunotherapeutic agent or antiangiogenic agent. A pharmaceutical composition, a method for the treatment of cancer in the form of solid tumor or hematological malignant neoplasm in a subject, a method for restoration or increase in susceptibility to anticancer immunotherapy in a subject, and a method for restoration or increase in susceptibility to an anticancer antiangiogenic agent in a subject are also disclosed.
EFFECT: group of inventions provides for a synergetic increase in the efficiency of cancer immunotherapy or cancellation of established resistance to a treatment means based on an antibody to VEGF.
29 cl, 5 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THIOCARBAMATE DERIVATIVES AS A2A INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS THEREOF WITH ANTICANCER AGENTS | 2019 |
|
RU2824502C2 |
| COMBINATION THERAPY WITH TETRACYCLIC QUINOLONE ANALOGUES FOR TREATMENT OF CANCER | 2016 |
|
RU2786570C2 |
| COMBINED THERAPY WITH TETRACYCLIC QUINOLONE ANALOGUES FOR CANCER TREATMENT | 2016 |
|
RU2752506C2 |
| PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS TAM AND MET KINASE INHIBITORS | 2019 |
|
RU2773611C1 |
| USING SMOOTHENED ANTAGONISTS FOR TREATING HEDGEHOG PATHWAY RELATED DISORDERS | 2009 |
|
RU2519200C2 |
| NEW SULPHONAMIDE DERIVATIVES WITH SELECTIVE NOX INHIBITORY ACTIVITY | 2019 |
|
RU2809030C2 |
| APPLICATION OF MEDICATIONS, BINDING EDG-RECEPTOR, IN TREATMENT OF CANCER DISEASE | 2008 |
|
RU2426555C2 |
| COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2368602C2 |
| DERIVATIVES OF ISOTHIOUREA AND METHOD OF THEIR PRODUCTION, THEIR APPLICATION AND PHARMACEUTICAL COMPOSITION | 2005 |
|
RU2376297C2 |
| APPLICATION OF EDG-RECEPTOR BINDING AGENT IN CANCER THERAPY | 2003 |
|
RU2358717C2 |
